Abstract
OBJECTIVE:To systematically review the efficacy of compound Xueshuantong capsules combined with angiotensin-converting enzyme inhibitors( ACEI)/angiotensin receptor blockers( ARB) in treatment of diabetic kidney disease( DKD) .METHODS: CJFD, VIP and Wanfang Database were retrieved to collect the randomized controlled trials( RCT) about the efficacy of compound Xueshuantong Capsules combined with ACRI/ARB in treatment of DKD till May.3rd , 2016, manual retrieval was adopted.Quality evaluation and Meta-analysis of included literatures were conducted.RESULTS: A total of 6 RCTs were included, involving 532 cases.Results of Meta-analysis showed that compound Xueshuantong capsules combined with ACEI/ARB ( test group) was better than that of ACEI/ARB( control group) in increasing clinical total effective rate(RR=1.33,95%CI=1.17-1.52,P<0.000 01), reducing UAER ( MD =-21.03 , 95%CI =-31.75--10.31 , P =0.000 1 ) , whole blood high-shear viscosity ( MD =-1.06 , 95%CI=-1.46--0.65,P<0.000 01), whole blood low-shear viscosity(MD=-1.78,95%CI=-3.43--0.12, P=0.04), TC (MD =-0.98,95%CI =-1.67--0.29,P =0.006), TG (MD =-0.40,95%CI =-0.67--0.13,P=0.004) and increasing HDL-C (MD=0.32,95%CI=0.10-0.55,P=0.005), there were statistically significant differences between two groups.And there was no significant difference in the FBG ( MD =-0.34, 95%CI=-1.14-0.45,P =0.40), PBG (MD =-0.84,95%CI =-2.67-0.99,P =0.37), HbA1c (MD =-0.02,95%CI=-0.19-0.15,P=0.37), BUN (MD=-0.16,95%CI=-0.59-0.27,P=0.46), Scr (MD=-9.19,95%CI=-8.72-3.55,P=0.16) and LDL-C (MD=-0.60,95%CI=-1.58--0.39,P=0.23) between two groups.CONCLUSIONS: The efficacy of compound Xueshuantong capsules combined with ACEI/ARB is better than only ACEI/ARB in treatment of DKD.关键词
血栓通/ACEI/ARB/糖尿病肾病/疗效/Meta分析Key words
Compound Xueshuantong capsules/ACEI/ARB/DKD/Efficacy/Meta-analysis分类
医药卫生
